title: A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab.
abstract: A 44-year-old woman presented with lower abdominal pain and bilateral ovarian masses on ultrasound. Exploratory laparotomy revealed extensive peritoneal and intra-abdominal disease and an abnormal appendix. Bilateral salpingo-oophorectomy, infracolic omentectomy, ileocolic resection and primary anastomosis were performed. Final pathology revealed a primary appendiceal adenocarcinoma, poorly differentiated, of signet ring cell type. CT scan postoperatively revealed gross residual disease. The patient was treated with FOLFOX chemotherapy combined with bevacizumab. Repeat CT scan showed a decrease in residual disease and the patient clinically improved. After her treatment has been continued for 13 months, she remains clinically well and her CT scan shows sustained disease stability. Disseminated appendiceal carcinoma is generally considered to be refractory to 5-FU-based chemotherapy and, to our knowledge, this is the first reported case of a patient with appendiceal adenocarcinoma demonstrating clinical benefit and sustained stability of disease with combination chemotherapy plus bevacizumab.
authors.affiliation: Departments of Medical Oncology, Radiology, and Pathology and Laboratory Medicine, Ottawa Regional Cancer Center, The Ottawa General Hospital, University of Ottawa, Ottawa, Ont., Canada.
authors.forename: Erin D
authors.initials: ED
authors.lastname: Powell
authors.forename: D Blair
authors.initials: DB
authors.lastname: Macdonald
authors.forename: Akram M
authors.initials: AM
authors.lastname: Elkeilani
authors.forename: Timothy R
authors.initials: TR
authors.lastname: Asmis